David Y. Mitchell, PhD, has over 30 years experience in clinical development, strategic drug development, and project leadership. Dr. Mitchell earned his PhD in pharmaceutical sciences from the University of Colorado and completed a postdoctoral fellowship in the Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas School of Medicine.
Dr. Mitchell has led clinical pharmacology programs at Pfizer and Procter & Gamble Pharmaceuticals in the areas of oncology, neuroscience, and bone disease while serving as the clinical pharmacokineticist, and has served as a global team leader at Pfizer, OSI Pharmaceuticals, and Array Biopharma in the areas of oncology and neuroscience. Since 2009, Dr. Mitchell has been a consultant in clinical pharmacology for small and large pharma and biotech companies working on drug candidates for oncology, neuroscience, inflammation, and rare diseases. He is currently a senior vice president at Certara, and was the former chief scientific officer at Nuventra Pharma Sciences. He has published more than 85 manuscripts, book chapters, and abstracts on pharmacokinetics, pharmacodynamics, metabolism, toxicology, and epidemiology, and is a co-inventor on a number of patents.
Dr. Mitchell is a past president and former board member for the American Association of Pharmaceutical Scientists and American Society of Clinical Pharmacology and Therapeutics, and has served as a volunteer in many other roles for over 25 years.